Cantor Fitzgerald initiates coverage of Celcuity with Overweight rating and $140 price target
Cantor Fitzgerald began covering Celcuity Inc., assigning an Overweight rating and a 12‑month price target of $140 per share. The firm highlighted the commercial launch of Revtorpyk, a breast‑cancer drug that serves about 60% of the second‑line HR+/HER2‑ patient pool, and projected a credible path to multi‑billion‑dollar peak sales. Analysts also noted the drug’s wholesale price of $10,000 per vial and an upcoming expansion to PIK3CA‑mutant patients next year.
Why it matters
The $140 target represents roughly 127% upside from the current price, suggesting significant upside potential for investors (the company’s note says). If Revtorpyk achieves the projected $2.7 billion peak sales, the company’s market value could rise substantially.
Key facts
- 1Cantor Fitzgerald initiated coverage of Celcuity with an Overweight rating and a $140 price target. tradingview.com
- 2Celcuity’s shares were trading at $61.56, giving the company a market cap of $3.01 billion. investing.com
- 3Revtorpyk targets approximately 60% of the second‑line HR+/HER2‑ breast cancer population. investing.com
- 4The wholesale acquisition cost of Revtorpyk is $10,000 per vial. investing.com
- 5Celcuity expects to expand Revtorpyk’s use to PIK3CA‑mutant patients next year, covering the full second‑line population. ibtimes.com.au
- 6Analysts estimate peak sales of $2.7 billion for Revtorpyk in the second‑line setting. tradingview.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.